VALUABLE: Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Sponsor
Paolo Ghia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04758975
Collaborator
(none)
55
1
67

Study Details

Study Description

Brief Summary

This is a Phase 2, multicenter, open-label uncontrolled interventional study aimed a determining therapeutic benefits of the addition of ibrutinib to 12 months of venetoclax (single-agent for 6 months then combined with rituximab for additional 6 months) in patients with treatment-naïve CLL based on a MRD-guided approach. Study treatment will be administered according to the following scheme:

VENETOCLAX: Cycle 1 Day 1-Cycle 1 Day 28 Ramp-up with weekly dose escalation; Cycles 2-12:

400 mg QD RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2

At the end of Cycle 12 the MRD status is checked:

3 consecutive uMRD in PB + 1 uMRD in BM at last assessment treatment discontinuation and follow-up At least 1 MRD+ sample in the last 3 assessments. Venetoclax 400 mg QD until uMRD or up to 24 months or unacceptable toxicity (whichever occurs first) in combination with IBRUTINIB 420 mg QD until uMRD or PD or unacceptable toxicity. Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase (Ramp-up Period). At Cycle 7 Day 1 rituximab will be added for up to 6 monthly cycles (Cycle 7 Day 1 rituximab 375 mg/m2, Cycles 8-12 Day 1 rituximab 500 mg/m2). At Cycle 12 Day 1, disease status, renal function and risk of bleeding will be assessed. Minimal residual disease (MRD) will be evaluated serially in both PB and, after 3 consecutive uMRD in PB, in BM. All subjects with uMRD (defined as those with MRD level <10-4 in the PB in 3 consecutive assessments and in a BM aspirate) will discontinue venetoclax at the end of Cycle 12 (i.e. Cycle 12 Day 28). All subjects with detectable MRD (defined as those with MRD level in the PB and/or BM >10-4) and patients with stable disease without any contraindications to ibrutinib will start treatment with ibrutinib. Ibrutinib will be administered at the standard dose in CLL (i.e. 420 mg QD). Venetoclax will be administered until confirmed uMRD (3 consecutive uMRD in PB, the last one with concomitant uMRD in BM), unacceptable toxicity or disease progression or for a maximum of 2 years and ibrutinib will be continued until unacceptable toxicity, confirmed uMRD or disease progression.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
55 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Venetoclax and Delayed Rituximab With Ibrutinib Consolidation Aiming at Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Venetoclax + Rituximab +/- Ibrutinib

VENETOCLAX: Cycle 1 Day 1-Cycle 1 Day 28 Ramp-up with weekly dose escalation; Cycles 2-12: 400 mg QD RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2 At the end of Cycle 12 the MRD status is checked: 3 consecutive uMRD in PB + 1 uMRD in BM at last assessment treatment discontinuation and follow-up At least 1 MRD+ sample in the last 3 assessments venetoclax 400 mg QD until uMRD or up to 24 months or unacceptable toxicity (whichever occurs first) in combination with IBRUTINIB 420 mg QD until uMRD or PD or unacceptable toxicity

Drug: Venetoclax
VENETOCLAX: Ramp-up than 400 mg QD

Drug: Rituximab
RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2

Drug: Ibrutinib
IBRUTINIB 420 mg QD

Outcome Measures

Primary Outcome Measures

  1. uMRD (<10-4) by 6-color flow cytometry in the bone marrow [27 months]

    uMRD (<10-4) by 6-color flow cytometry in the bone marrow as best response at any time during treatment for up to 3 months after completion of combined therapy (VR or VR followed by VI)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age ≥18 years but <65 years

  2. Active CLL/SLL requiring treatment per iwCLL 2018 criteria

  3. No previous therapy for CLL/SLL

  4. Adequate bone marrow function:

  5. ANC ≥1.0 x 109/L;

  6. Plt ≥25 x 109/L;

  7. Hgb ≥8.0 g/dl

Exclusion Criteria:
  1. Any prior therapy used for treatment of CLL or SLL

  2. History of other malignancies, except in situ carcinoma or malignancy treated with curative intent

  3. Known or suspected history of Richter's transformation

  4. Known hypersensitivity to one or more study drugs

  5. Inadequate renal function: CrCl <30 mL/min

  6. Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia

  7. Requires the use of warfarin or derivatives

  8. Treatment with any of the following within 7 days prior to the first dose of study drug:

  9. Steroid therapy for anti-neoplastic intent

  10. Moderate or strong cytochrome P450 3A (CYP3A) inhibitors (see Appendix G for examples)

  11. Moderate or strong CYP3A inducers (see Appendix G for examples)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Paolo Ghia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Paolo Ghia, Professor, IRCCS San Raffaele
ClinicalTrials.gov Identifier:
NCT04758975
Other Study ID Numbers:
  • PS-CLL-009
First Posted:
Feb 17, 2021
Last Update Posted:
Apr 5, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 5, 2022